Onceweekly tirzepatide versus oncedaily insulin degludec as addon to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS3): a randomised, openlabel, parallelgroup, phase 3 trial
STEP 1 shows that those in the treatment group (with all the limitations weve talked about) lost an average of 4.5% more than those in the SELECT trial compared to their respective placebo groups
Any information provided on this website is for informational purposes only
It is an effective weight loss drug, functioning by mimicking a satiety hormone, reducing appetite, and slowing gastric emptying
Zhang et al., 2023), cardiomyopathy (Zhou et al., 2023), intestinal inflammation (Motilva et al., 2011
Restores supply chain team has verified that our partner pharmacies use active ingredients consistent with those in well-known FDA-approved weight-loss medications